← Leaderboards
Christopher Marr Gromisch
Boston University Medical Campus
$150,060
Attributed
$150,060
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $50.5K · FY2018–20$100K$75K$50K$25K$0
'18
'19
'20
Funding mix
By agency
NIH$150,060 · 1
By mechanism
F30$150,060 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Thomas William Geisbert$89,759,942
- Kevin Whaley$2,620,801
- John C. Samuelson$11,778,804
- Alex Luebbers$137,804
- Nelson Ruiz-Opazo$8,357,592
Others in their field
Other Emerging Leaders on “Advanced Development”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Joel A Lipkin · Four Points Technology, Llc$181,896,915
- Kimberly Smith · Ppd Development Lp$115,671,664
Research focus
Advanced DevelopmentAmericanAmerican Society Of Clinical OncologyAntibodiesAntibody ConjugateAntibody-Drug ConjugatesAntibody TherapyAntigensApoptosisApoptoticApplied ResearchBaseBasic ScienceBindingBiocompatible MaterialsBiologyBiomedical EngineeringBirc3 GeneBostonCancer BiologyCancer CellCancer Stem CellCareerAdenocarcinoma Cell
Grant awards (3)
Development of a novel Antibody Drug Conjugate for the treatment of pancreaticcancer$50,520
F30 · FY2020 · CA · contact PI
Development of a novel Antibody Drug Conjugate for the treatment of pancreaticcancer$50,016
F30 · FY2019 · CA · contact PI
Development of a novel Antibody Drug Conjugate for the treatment of pancreaticcancer$49,524
F30 · FY2018 · CA · contact PI